About: Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study
Creator	Rello, Jordi Erdem, Hakan Cag, Yasemin Uygun, Yesim Hasbun, Rodrigo Aslan, Emel Batirel, Ayse Dogan, Mustafa Dogru, Arzu Durmus, Gul Gencer, Serap Guler, Selma Harman, Rezan Karabay, Oguz Karakurt, Zuhal Meric-Koc, Meliha Mutlu-Yilmaz, Esmeray Oncu, Serkan Sener, Alper Tosun, Selma Turan, Hale Ulug, Mehmet Uysal, Serhat
Source	PMC
abstract	Ventilator-associated pneumonia (VAP) due to Acinetobacter spp. is one of the most common infections in the intensive care unit. Hence, we performed this prospective-observational multicenter study, and described the course and outcome of the disease. This study was performed in 24 centers between January 06, 2014, and December 02, 2016. The patients were evaluated at time of pneumonia diagnosis, when culture results were available, and at 72 h, at the 7th day, and finally at the 28th day of follow-up. Patients with coexistent infections were excluded and only those with a first VAP episode were enrolled. Logistic regression analysis was performed. A total of 177 patients were included; empiric antimicrobial therapy was appropriate (when the patient received at least one antibiotic that the infecting strain was ultimately shown to be susceptible) in only 69 (39%) patients. During the 28-day period, antibiotics were modified for side effects in 27 (15.2%) patients and renal dose adjustment was made in 38 (21.5%). Ultimately, 89 (50.3%) patients died. Predictors of mortality were creatinine level (OR, 1.84 (95% CI 1.279–2.657); p = 0.001), fever (OR, 0.663 (95% CI 0.454–0.967); p = 0.033), malignancy (OR, 7.095 (95% CI 2.142–23.500); p = 0.001), congestive heart failure (OR, 2.341 (95% CI 1.046–5.239); p = 0.038), appropriate empiric antimicrobial treatment (OR, 0.445 (95% CI 0.216–0.914); p = 0.027), and surgery in the last month (OR, 0.137 (95% CI 0.037–0.499); p = 0.003). Appropriate empiric antimicrobial treatment in VAP due to Acinetobacter spp. was associated with survival while renal injury and comorbid conditions increased mortality. Hence, early diagnosis and appropriate antibiotic therapy remain crucial to improve outcomes.
has issue date	2019-09-09(xsd:dateTime)
bibo:doi	10.1007/s10096-019-03691-z
bibo:pmid	31502120
has license	no-cc
sha1sum (hex)	42370f6da83f28a358acd32dc18b4287d9786705
schema:url	https://doi.org/10.1007/s10096-019-03691-z
resource representing a document's title	Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study
has PubMed Central identifier	PMC7222138
has PubMed identifier	31502120
schema:publication	Eur J Clin Microbiol Infect Dis
resource representing a document's body	covid:42370f6da83f28a358acd32dc18b4287d9786705#body_text
is schema:about of	named entity 'patients' named entity 'infections' named entity 'received' named entity 'ventilator-associated pneumonia' named entity 'Acinetobacter' named entity 'STUDY' named entity 'ENROLLED' named entity 'During' named entity 'antimicrobial therapy' named entity 'day' named entity 'time' named entity 'antibiotics' named entity 'patients' named entity 'intensive care unit' named entity 'comorbid' named entity '2014' named entity 'congestive heart failure' named entity 'study' named entity 'December' named entity 'fever' named entity 'antimicrobial therapy' named entity 'regression analysis' named entity 'antibiotic' named entity 'culture results' named entity 'Ventilator-associated pneumonia' named entity 'early diagnosis' named entity 'Acinetobacter spp' named entity 'ventilator-associated pneumonia' named entity 'fever' named entity 'Multidrug resistance' named entity 'antimicrobial' named entity 'Student's t test' named entity 'broth microdilution' named entity 'non-parametric' named entity 'prognostic' named entity 'MCAR' named entity 'antibiotic susceptibility' named entity 'sodium' named entity 'AST' named entity 'critically ill' named entity 'ICUs' named entity 'treatment of patients' named entity 'antibiotics' named entity 'phase III' named entity 'randomized controlled trial' named entity 'non-parametric' named entity 'MALDI-TOF MS' named entity 'MCAR' named entity 'missing completely at random' named entity 'VAP' named entity 'creatinine levels' named entity 'fever' named entity 'Acinetobacter' named entity 'invasive procedures' named entity 'antimicrobial therapy' named entity 'follow-up' named entity 'pneumonia' named entity 'tigecycline' named entity 'intensive care unit'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software